Wells Fargo’s GT Biopharma GTBP Stock Holding History

Wells Fargo’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.83K	Sell	639 -2	-0.3%	-$20	﹤0.01%	6131
2026 Q1	$6.54K	Hold	641	–	–	﹤0.01%	6056
2025 Q4	$12.6K	Buy	641 +241	+60%	+$4.28K	﹤0.01%	5901
2025 Q3	$5.87K	Hold	400	–	–	﹤0.01%	6048
2025 Q2	$35.8K	Sell	400 -1	-0.2%	-$65	﹤0.01%	5619
2025 Q1	$21.5K	Hold	401	–	–	﹤0.01%	5685
2024 Q4	$30.5K	Hold	401	–	–	﹤0.01%	5637
2024 Q3	$23.1K	Hold	401	–	–	﹤0.01%	5605
2024 Q2	$28.3K	Hold	401	–	–	﹤0.01%	5487
2024 Q1	$44.4K	Hold	401	–	–	﹤0.01%	5305
2023 Q4	$76.7K	Hold	401	–	–	﹤0.01%	5069
2023 Q3	$72.5K	Buy	401 +267	+199%	+$55.2K	﹤0.01%	4965
2023 Q2	$31.4K	Hold	134	–	–	﹤0.01%	5607
2023 Q1	$55.3K	Hold	134	–	–	﹤0.01%	5115
2022 Q4	$89.1K	Buy	134 +133	+13,300%	+$166K	﹤0.01%	4595
2022 Q3	$1K	Hold	1	–	–	﹤0.01%	6351
2022 Q2	$2K	Sell	1 -39	-98%	-$73.9K	﹤0.01%	6322
2022 Q1	$87K	Buy	40 +26	+186%	+$57.3K	﹤0.01%	5395
2021 Q4	$32K	Buy	14 +12	+600%	+$44.9K	﹤0.01%	6167
2021 Q3	$13K	Buy	2 +1	+100%	+$7.52K	﹤0.01%	6112
2021 Q2	$6K	Buy	+1	New	+$10.4K	﹤0.01%	6282
2021 Q1	–	Hold	0	–	–	–	6719

Other funds holding GTBP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

OWA

Opal Wealth Advisors Jericho, New York $479M AUM 15.43% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

4WM

49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return

Alongside Austin, Texas $525M AUM

Wells Fargo's GTBP Position: Q2 2026 in Review

Wells Fargo reduced its GT Biopharma (GTBP) stake by 0.31% in Q2 2026, selling an estimated $20 and leaving 639 shares worth $7.83K. The position accounts for ﹤0.01% of the portfolio, ranked #6131.

Wells Fargo first reported a position in GTBP in Q2 2021 and has held it in 21 quarters since. The position peaked at $89.1K in Q4 2022. 55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

Wells Fargo held 639 shares of GT Biopharma worth $7.83K as of Q2 2026.
Wells Fargo sold 2 GT Biopharma shares in Q2 2026, an estimated $20.
GT Biopharma made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6131 holding.
Wells Fargo first reported a position in GT Biopharma in Q2 2021 and has held it in 21 quarters since.
Wells Fargo's GT Biopharma position peaked at $89.1K in Q4 2022.
55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.